Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021

Grisanti, Salvatore; Cosentini, Deborah; Sigala, Sandra; Berruti, Alfredo

doi:10.1097/cco.0000000000000799

Cited by 5 publications

(2 citation statements)

References 84 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CU-ACC1 cell line derives from a perinephric ACC metastasis [ 41 ] and secretes higher levels of cortisol compared to NCI-H295R cells, while no aldosterone secretion was reported. Genetic analysis reveals an activating point mutation of CTNNB1 gene [ 41 ], a well known ACC driver gene [ 42 ]. The CU-ACC2 cell line was established from a liver metastasis in a Lynch syndrome patient with non-secreting primary ACC [ 41 ].…”

Section: Cu-acc1 and Cu-acc2mentioning

confidence: 99%

An update on adrenocortical cell lines of human origin

et al. 2022

Self Cite

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease. Management of ACC is dependent on disease stage with complete surgical resection as the only potentially curative option. However, advanced, un-resectable, metastatic stages and also recurrences often require systemic treatments, which are unfortunately nowadays still unsatisfactory. The scarcity of preclinical models reflecting patient heterogeneities and furthermore drug-resistant phenotypes, has hampered the progress and development of new therapies in recent years. In this review, we provide an overview on the classical models and substantial progress which has been made over the last years in context of this aggressive disease.

show abstract

Section: Cu-acc1 and Cu-acc2mentioning

confidence: 99%

An update on adrenocortical cell lines of human origin

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…

…”

mentioning

confidence: 99%

Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1–2, 2021

Berruti

Terzolo

2022

Endocrine

Self Cite

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is an extremely rare malignancy, whose molecular pathogenesis is incompletely understood [1] and treatment strategies are limited [2]. An international Symposium, held in Ann Arbor in 2003 [3], stimulated international collaborations. Since then, the ACC international research community has grown over time and meets every 2 years in a Symposium where advances in the pathogenesis and therapy of this rare disease are discussed. The 8th edition of this Symposium was organized by Alfredo Berruti and Massimo Terzolo and was held in Brescia from September 30 to October 2, in a Webinar mode due to SARS COV-2 pandemic. The webinar organization favored the widespread of Conference, which attracted more than 600 scientists from different countries. The 2021 meeting covered a broad range of topics related to advances in preclinical and clinical researches. It was organized in a number of sessions, aligned to a specific theme, research area or clinical issue. Sessions included lectures and oral communications on leading research related to molecular heterogeneity of adrenocortical tumors, new insights from preclinical studies, progress in surgical treatment, adjuvant therapies, management of advanced disease and future perspectives and proposals of new clinical studies. As previous editions, this productive Symposium served to educate, enhance discovery, and facilitate the development of effective strategies for this rare disease.

show abstract